Emicizumab is a bispecific antibody with 2 binding sites, 1 each for activated FIX (FIXa) and FX, bringing them together in a way that mimics the role of missing FVIIIa in hemophilia A. https://t.co/YDFpirU2zO https://t.co/nSamF69fIk
RT @StanfordChiefs: 2) In hemophilia A, we can bypass factor VIII by using emicizumab, which binds the active factor IX to factor X, and le…
2) In hemophilia A, we can bypass factor VIII by using emicizumab, which binds the active factor IX to factor X, and lets factor IXa activate factor X directly! This can potentially reduce the amount of recombinant factor VIII you need to give. [2/4] https
RT @ProfMakris: Another #emicizumab (#Hemlibra) review with free PDF. The top right hand cell of table 1 is the most interesting for me. Wi…
Another #emicizumab (#Hemlibra) review with free PDF. The top right hand cell of table 1 is the most interesting for me. With 0.3mg/kg (ie 20% of the licensed dose) the ABR after 12 weeks was 1.4. We need an RCT of 0.3mg/kg vs 1.5mg/kg. https://t.co/lYM80I